CAFC: Mere ANDA Filing Not Willful Infringement

On July 27, 2004, the U.S. Court of Appeals for the Federal Circuit stated in Glaxo Group v. Apotex that "[An ANDA] a filing cannot constitute willful infringement for purposes of establishing an exceptional case and the award of attorney’s fees under 35 U.S.C. § 271(e)(4)."  Click here for  more information about Abbreviated New Drug Applications.